News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Human Genome Sciences, Inc.'s Lupus Drug Draws Questions; FDA Forms Advisory Committee
November 15, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, Nov 12 (Reuters) - U.S. drug reviewers questioned if the benefits of a long-awaited Human Genome Sciences Inc (HGSI.O) lupus drug outweighed concerns about suicide and other possible risks, but analysts said they still expected approval.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Prostate cancer
AstraZeneca’s Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails
April 30, 2025
·
2 min read
·
Tristan Manalac
Vaccines
HHS Unfreezes Vaxart’s COVID-19 Study, Resumes Funding as Headwinds Batter Vaccines Space
April 29, 2025
·
2 min read
·
Tristan Manalac
Bladder cancer
Pfizer’s Subcutaneous PD-1 Cuts Risks in Bladder Cancer but Misses Survival Endpoint
April 28, 2025
·
1 min read
·
Tristan Manalac
Bladder cancer
J&J Declares ‘Sustained Disease Control’ With Bladder Cancer Drug-Device Combo
April 28, 2025
·
2 min read
·
Tristan Manalac